Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

In this cohort study of 1552 patients with non–small cell lung cancer, the group with high tumor mutation burden (TMB) had improved response rates and survival after receiving programmed cell death–1/programmed death ligand–1 (PD-L1) inhibition therapy across PD-L1 expression subgroups compared with the group with low TMB.